Compare DAN & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAN | RCUS |
|---|---|---|
| Founded | 1904 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.8B |
| IPO Year | 2002 | 2018 |
| Metric | DAN | RCUS |
|---|---|---|
| Price | $26.59 | $27.77 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $40.60 | $31.90 |
| AVG Volume (30 Days) | ★ 2.0M | 1.5M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.34% | N/A |
| EPS Growth | ★ 264.10 | N/A |
| EPS | ★ 9.89 | N/A |
| Revenue | ★ $7,500,000,000.00 | $247,000,000.00 |
| Revenue This Year | $1.89 | N/A |
| Revenue Next Year | $4.59 | $45.62 |
| P/E Ratio | $2.72 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.31 | $8.84 |
| 52 Week High | $39.56 | $31.74 |
| Indicator | DAN | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 39.73 | 48.46 |
| Support Level | $24.60 | $20.20 |
| Resistance Level | $31.73 | $28.72 |
| Average True Range (ATR) | 1.02 | 1.37 |
| MACD | 0.31 | -0.48 |
| Stochastic Oscillator | 54.90 | 28.74 |
Dana Inc is provider of products to virtually every vehicle manufacturer in the world. Its technologies include drive systems (axles, driveshafts and transmissions); electrodynamic technologies (motors, inverters, software and control systems, battery-management systems, and fuel cell plates); sealing solutions (gaskets, seals, cam covers, and oil pan modules); thermal-management technologies (transmission and engine oil cooling, battery and electronics cooling, charge air cooling, and thermal-acoustical protective shielding); and digital solutions (active and passive system controls and descriptive and predictive analytics). The company has two operating segments: Light Vehicle and Commercial Vehicle. The Light Vehicles segment generates the majority of revenue.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.